- Advanced NSCLC
- Prior treatment with and failure of at least one regimen of chemotherapy and
erlotinib or gefitinib
- Prior treatment with no more than two chemotherapy regimens, including adjuvant
treatment
- Measurable disease
- Chemotherapy, radiotherapy, biological or investigational agents within 4 weeks of
baseline disease assessment
- Patients who lack of tolerance of erlotinib therapy
- Patients with known brain Metastases
- Patients with demonstrated history of or presence of interstitial lung disease.